Anthera Pharmaceuticals, Inc. (ANTH) Lifted to Buy at Zacks Investment Research

Anthera Pharmaceuticals, Inc. (NASDAQ:ANTH) was upgraded by Zacks Investment Research from a “hold” rating to a “buy” rating in a report released on Tuesday. The firm currently has a $2.00 price target on the biopharmaceutical company’s stock. Zacks Investment Research‘s target price indicates a potential upside of 11.73% from the company’s previous close.

According to Zacks, “Anthera Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing and commercializing products to treat serious illnesses, including cardiovascular and autoimmune diseases. The Company’s clinical-stage programs include one Phase 3 ready program, A-002, and two Phase 2 clinical programs, A-623 and A-001. A-002 and A-001 inhibit a novel enzyme target known as secretory phospholipase A2, or sPLA2. Elevated levels of sPLA2 have been implicated in a variety of acute inflammatory conditions, including acute coronary syndrome and acute chest syndrome, as well as chronic diseases such as stable coronary artery disease. A-623 targets elevated levels of B-lymphocyte stimulator, or BLyS (also known as BAFF), which has been associated with a variety of B-cell mediated autoimmune diseases, including systemic lupus erythematosus (SLE), rheumatoid arthritis, multiple sclerosis, Sjögren’s Syndrome, Graves’ Disease and others. Anthera Pharmaceuticals, Inc. is headquartered in Hayward, California. “

ANTH has been the subject of a number of other research reports. Jefferies Group LLC reaffirmed a “hold” rating and set a $1.75 target price (down previously from $2.25) on shares of Anthera Pharmaceuticals in a report on Friday, August 11th. ValuEngine upgraded Anthera Pharmaceuticals from a “strong sell” rating to a “sell” rating in a research report on Friday, September 1st. Finally, HC Wainwright reiterated a “buy” rating and set a $3.00 price target on shares of Anthera Pharmaceuticals in a research report on Tuesday, September 19th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and three have given a buy rating to the stock. The company has an average rating of “Hold” and an average price target of $5.11.

Anthera Pharmaceuticals (ANTH) traded up 4.07% during midday trading on Tuesday, hitting $1.79. 541,827 shares of the stock traded hands. The company has a 50-day moving average of $1.45 and a 200-day moving average of $1.38. Anthera Pharmaceuticals has a 12 month low of $1.20 and a 12 month high of $3.22. The stock’s market cap is $19.52 million.

Anthera Pharmaceuticals (NASDAQ:ANTH) last released its earnings results on Wednesday, August 9th. The biopharmaceutical company reported $0.03 EPS for the quarter, topping the Zacks’ consensus estimate of ($1.09) by $1.12. On average, equities research analysts anticipate that Anthera Pharmaceuticals will post ($3.68) earnings per share for the current year.

ILLEGAL ACTIVITY WARNING: “Anthera Pharmaceuticals, Inc. (ANTH) Lifted to Buy at Zacks Investment Research” was originally reported by Markets Daily and is owned by of Markets Daily. If you are viewing this piece of content on another domain, it was illegally copied and republished in violation of U.S. & international copyright and trademark legislation. The legal version of this piece of content can be accessed at https://www.themarketsdaily.com/2017/10/10/anthera-pharmaceuticals-inc-anth-lifted-to-buy-at-zacks-investment-research.html.

Several institutional investors have recently bought and sold shares of the company. Goldman Sachs Group Inc. increased its position in shares of Anthera Pharmaceuticals by 1,376.1% in the first quarter. Goldman Sachs Group Inc. now owns 359,982 shares of the biopharmaceutical company’s stock valued at $153,000 after buying an additional 335,595 shares in the last quarter. Sabby Management LLC increased its position in shares of Anthera Pharmaceuticals by 1,809.7% in the first quarter. Sabby Management LLC now owns 1,757,697 shares of the biopharmaceutical company’s stock valued at $748,000 after buying an additional 1,665,655 shares in the last quarter. Finally, UBS Group AG increased its position in shares of Anthera Pharmaceuticals by 9.9% in the first quarter. UBS Group AG now owns 375,989 shares of the biopharmaceutical company’s stock valued at $160,000 after buying an additional 33,901 shares in the last quarter. Institutional investors and hedge funds own 27.26% of the company’s stock.

About Anthera Pharmaceuticals

Anthera Pharmaceuticals, Inc (Anthera) is a biopharmaceutical company focused on developing and commercializing products to treat serious diseases associated with inflammation, including enzyme replacement therapies and autoimmune diseases. The Company has two Phase III product candidates, liprotamase also known as Sollpura and blisibimod.

Analyst Recommendations for Anthera Pharmaceuticals (NASDAQ:ANTH)

Receive News & Ratings for Anthera Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anthera Pharmaceuticals Inc. and related companies with MarketBeat.com's FREE daily email newsletter.

Latest News

Leave a Reply